Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CHEK2 Biologics Sequence Review Report 2026: Serine/threonine-protein kinase Chk2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CHEK2 Biologics Sequence Review Report 2026: Serine/threonine-protein kinase Chk2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CHEK2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BUB1B Biologics Sequence Review Report 2026: Mitotic checkpoint serine/threonine-protein kinase BUB1 beta Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BUB1B Biologics Sequence Review Report 2026: Mitotic checkpoint serine/threonine-protein kinase BUB1 beta Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of BUB1B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BUB1 Biologics Sequence Review Report 2026: Mitotic checkpoint serine/threonine-protein kinase BUB1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BUB1 Biologics Sequence Review Report 2026: Mitotic checkpoint serine/threonine-protein kinase BUB1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of BUB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CHEK1 Biologics Sequence Review Report 2026: Serine/threonine-protein kinase Chk1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CHEK1 Biologics Sequence Review Report 2026: Serine/threonine-protein kinase Chk1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CHEK1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PLIN3 Biologics Sequence Review Report 2026: Perilipin-3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PLIN3 Biologics Sequence Review Report 2026: Perilipin-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PLIN3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GFRA3 Biologics Sequence Review Report 2026: GDNF family receptor alpha-3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GFRA3 Biologics Sequence Review Report 2026: GDNF family receptor alpha-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GFRA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GSDME Biologics Sequence Review Report 2026: Gasdermin-E Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GSDME Biologics Sequence Review Report 2026: Gasdermin-E Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GSDME protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GRIN3B Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, NMDA 3B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GRIN3B Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, NMDA 3B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRIN3B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MED14 Biologics Sequence Review Report 2026: Mediator of RNA polymerase II transcription subunit 14 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MED14 Biologics Sequence Review Report 2026: Mediator of RNA polymerase II transcription subunit 14 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of MED14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNA2 Biologics Sequence Review Report 2026: Ephrin-A2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNA2 Biologics Sequence Review Report 2026: Ephrin-A2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of EFNA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TYROBP Biologics Sequence Review Report 2026: TYRO protein tyrosine kinase-binding protein Similarity and Patent-Risk Signals
8 min read
TYROBP Biologics Sequence Review Report 2026: TYRO protein tyrosine kinase-binding protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TYROBP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CYTH3 Biologics Sequence Review Report 2026: Cytohesin-3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CYTH3 Biologics Sequence Review Report 2026: Cytohesin-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CYTH3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →